Inactive Instrument

Vical Incorporated Nasdaq

Equities

US9256022032

Biotechnology & Medical Research

Vical to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

September 06, 2017 at 03:01 pm EDT

SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Tuesday, September 12, at 10:50 a.m. ET at the Rodman & Renshaw 19^th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017, at Lotte New York Palace Hotel in New York City. A webcast of the company’s presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.

About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.

Contact:
Andrew Hopkins
(858) 646-1127
Website:  www.vical.com

Primary Logo

Latest news about Vical Incorporated

Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index	Dec. 21	CI
Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index	Dec. 18	CI
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	23-09-20	MT
US Futures Rise Modestly Pre-Bell as Investors Await Fed Rate Decision	23-09-20	MT
Top Premarket Gainers	23-09-20	MT
Fresh Tracks Therapeutics' Board Approves Liquidation Plan; Shares Rise After Hours	23-09-19	MT
Fresh Tracks Therapeutics, Inc. Announces Chief Executive Officer Changes	23-09-19	CI
Fresh Tracks Therapeutics, Inc. Announces Executive Changes	23-09-19	CI
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately	23-07-25	CI
Wall Street Set to Open Higher, Investors Look to End Week on Positive Note	23-07-21	MT
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Earnings Flash (BBI) FRESH TRACKS THERAPEUTICS Posts Q1 Revenue $9,000	23-05-10	MT
Fresh Tracks Therapeutics, Inc. Announces Resignation of Gary A. Lyons from the Board of Directors	23-04-27	CI
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Earnings Flash (BBI) FRESH TRACKS THERAPEUTICS Posts Q4 Revenue $2.1M	23-03-30	MT
Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-30	CI
North American Morning Briefing : Stock Futures -2-	23-03-21	DJ
North American Morning Briefing : CPI Print Takes -3-	23-03-14	DJ
Investors Cautious Ahead of More Powell Testimony, Stifling US Equity Futures	23-03-08	MT
Top Premarket Gainers	23-03-08	MT
North American Morning Briefing : Stock Futures Struggle as More Powell Talk Looms	23-03-08	DJ
Fresh Tracks Therapeutics, Inc. Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02	23-03-07	CI

Chart Vical Incorporated

Duration

Period

More charts

Company Profile

Fresh Tracks Therapeutics, Inc. is not engaged in any business activities. The Company is in the process of dissolution.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.39%	102B
REGENERON PHARMACEUTICALS, INC.	+2.61%	96.84B
ARGENX SE	-0.67%	21.48B
BIONTECH SE	-18.14%	20.82B
GENMAB A/S	-7.22%	18.6B
WUXI APPTEC CO., LTD.	-40.70%	16.81B
BEIGENE, LTD.	-26.89%	13.78B
NEUROCRINE BIOSCIENCES, INC.	+1.12%	13.4B
SAREPTA THERAPEUTICS, INC.	+22.25%	11.06B

Bio Therapeutic Drugs